Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165256 · ClinicalTrials.gov registry record · Phase 2
Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast
A Phase 2 study of Ductal Carcinoma in Situ of the Breast, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
- 2
- Study locations
NCT00165256 is a Phase 2 study of Ductal Carcinoma in Situ of the Breast that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 158 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00165256, a Phase 2 study of Ductal Carcinoma in Situ of the Breast, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 1995-05 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165256
The ClinicalTrials.gov registry entry for NCT00165256 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ductal Carcinoma in Situ of the Breast appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT00165256 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165256 about?
NCT00165256 is a clinical study titled "Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast". The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.
What is the current status of trial NCT00165256?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 1995-05. Estimated completion is 2027-12.
What conditions does trial NCT00165256 study?
This clinical trial studies the following conditions: Ductal Carcinoma in Situ of the Breast.
What interventions are being tested in trial NCT00165256?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT00165256?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165256 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.